EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Modulation of TTR gene expression in the eye using modified siRNAs

Jiaxin Hu, Xin Gong, Jayanta Kundu, Dhrubajyoti Datta, Martin Egli iD, Muthiah Manoharan iD, V Vinod Mootha, David R Corey iD

Nucleic Acids Research · 2025

DOI: 10.1093/nar/gkaf409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, 2025. Verfasst von Jiaxin Hu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, United States. Hauptthemen laut MEDLINE: Prealbumin, RNA, Small Interfering, Eye, Gene Expression Regulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research to Prevent Blindness, NIH HHS, NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small interfering RNAs (siRNAs) are a proven therapeutic approach for controlling gene expression in the liver. Expanding the clinical potential of RNA interference requires developing strategies to enhance delivery to extra-hepatic tissues. In this study, we examine inhibiting transthyretin (TTR) gene expression by siRNAs in the eye. Anti-TTR siRNAs have been developed as successful drugs to treat TTR amyloidosis. When administered systemically, anti-TTR siRNAs alleviate symptoms by blocking TTR expression in the liver. However, TTR amyloidosis also affects the eye, suggesting a need for reducing ocular TTR gene expression. Here, we demonstrate that pyrimidine C5- and 2′-O-linked lipid-modified siRNAs formulated in saline can inhibit TTR expression in the eye when administered locally by intravitreal injection. Modeling suggests that length and accessibility of the lipid chains contribute to in vivo silencing. GalNAc-modified siRNAs also inhibit TTR expression, albeit less potently. These data support lipid-modified siRNAs as an approach to treating the ocular consequences of TTR amyloidosis. Inhibition of TTR expression throughout the eye demonstrates that lipid–siRNA conjugates have the potential to be a versatile platform for ocular drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrealbuminRNA, Small InterferingEyeGene Expression RegulationAnimalsMiceHumansRNA InterferenceAmyloid Neuropathies, FamilialLipidsAcetylgalactosaminePyrimidines

Substanzen

PrealbuminRNA, Small InterferingLipidsAcetylgalactosaminePyrimidines

Autor:innen und Institutionen

  • Departments of Pharmacology and Biochemistry, UT Southwestern Medical Center, Dallas, TX 75390, United States.
  • Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75235, United States.
  • Alnylam Pharmaceuticals, Cambridge, MA 04142, United States.
  • Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, TN 37232, United States.
  • Eugene McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX 75235, United States.

ORCID-Profile: Martin Egli, Muthiah Manoharan, David R Corey

Förderung

  • Research to Prevent Blindness
  • NIH HHS
  • NEI NIH HHS
  • Welch Foundation
  • NIGMS NIH HHS
  • National Institutes of Health

Zitieren

APA

Hu, J., Gong, X., Kundu, J., Datta, D., Egli, M., Manoharan, M., Mootha, V. V., & Corey, D. R. (2025). Modulation of TTR gene expression in the eye using modified siRNAs. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf409

Vancouver

Hu J, Gong X, Kundu J, Datta D, Egli M, Manoharan M, et al. Modulation of TTR gene expression in the eye using modified siRNAs. Nucleic Acids Research. 2025. doi:10.1093/nar/gkaf409

BibTeX
@article{Hu2025,
  author = {Hu, Jiaxin and Gong, Xin and Kundu, Jayanta and Datta, Dhrubajyoti and Egli, Martin and Manoharan, Muthiah and Mootha, V Vinod and Corey, David R},
  title = {Modulation of TTR gene expression in the eye using modified siRNAs},
  journal = {Nucleic Acids Research},
  year = {2025},
  doi = {10.1093/nar/gkaf409}
}
Kostenlos starten →